Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of MG1111 as 2nd Varicella Vaccination in Children
NCT05422508Phase 2Recruiting
- Sponsor
- GC Biopharma
- Start
- Jul 2022
- Primary completion
- Jun 2025
- Modality
- Prophylactic Vaccines, DNA Vaccines, Live Biotherapeutic Products
- Countries
- 1
01
Overview
A Phase 2 trial of varicella virus vaccine live in varicella (VZV), sponsored by GC Biopharma. Started Jul 2022; status: recruiting.
02
Drugs
varicella virus vaccine live
03
Conditions
varicella (VZV)
Beyond the preview
Go deeper on NCT05422508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05422508.